Invenio Wealth Partners LLC Buys 749 Shares of Colgate-Palmolive Company $CL

Invenio Wealth Partners LLC raised its position in shares of Colgate-Palmolive Company (NYSE:CL) by 29.4% in the 2nd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 3,297 shares of the company’s stock after purchasing an additional 749 shares during the period. Invenio Wealth Partners LLC’s holdings in Colgate-Palmolive were worth $300,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other large investors have also bought and sold shares of the company. Frank Rimerman Advisors LLC lifted its position in shares of Colgate-Palmolive by 29.9% during the 2nd quarter. Frank Rimerman Advisors LLC now owns 8,462 shares of the company’s stock valued at $769,000 after buying an additional 1,947 shares during the last quarter. Dorsey & Whitney Trust CO LLC raised its stake in Colgate-Palmolive by 1.6% in the 2nd quarter. Dorsey & Whitney Trust CO LLC now owns 17,158 shares of the company’s stock valued at $1,560,000 after acquiring an additional 267 shares during the period. Rothschild Investment LLC lifted its holdings in Colgate-Palmolive by 4.8% during the second quarter. Rothschild Investment LLC now owns 5,375 shares of the company’s stock valued at $489,000 after purchasing an additional 247 shares during the last quarter. Raiffeisen Bank International AG boosted its position in Colgate-Palmolive by 1.6% during the second quarter. Raiffeisen Bank International AG now owns 435,472 shares of the company’s stock worth $38,234,000 after purchasing an additional 6,885 shares during the period. Finally, Westpac Banking Corp increased its stake in shares of Colgate-Palmolive by 26.3% in the second quarter. Westpac Banking Corp now owns 106,760 shares of the company’s stock worth $9,704,000 after purchasing an additional 22,244 shares in the last quarter. 80.41% of the stock is owned by hedge funds and other institutional investors.

Colgate-Palmolive Price Performance

Colgate-Palmolive stock opened at $78.86 on Tuesday. The stock has a market cap of $63.57 billion, a price-to-earnings ratio of 22.15, a PEG ratio of 4.44 and a beta of 0.35. The company has a quick ratio of 0.57, a current ratio of 0.89 and a debt-to-equity ratio of 6.79. The business has a 50-day simple moving average of $79.08 and a 200 day simple moving average of $85.07. Colgate-Palmolive Company has a 52 week low of $74.54 and a 52 week high of $100.18.

Colgate-Palmolive (NYSE:CL) last released its quarterly earnings results on Friday, October 31st. The company reported $0.91 earnings per share for the quarter, beating the consensus estimate of $0.89 by $0.02. Colgate-Palmolive had a return on equity of 377.63% and a net margin of 14.55%.The firm had revenue of $5.13 billion for the quarter, compared to analysts’ expectations of $5.17 billion. During the same quarter last year, the firm posted $0.91 EPS. The company’s revenue was up 1.9% compared to the same quarter last year. On average, research analysts forecast that Colgate-Palmolive Company will post 3.75 earnings per share for the current fiscal year.

Colgate-Palmolive Announces Dividend

The business also recently declared a quarterly dividend, which was paid on Friday, November 14th. Shareholders of record on Friday, October 17th were paid a $0.52 dividend. This represents a $2.08 dividend on an annualized basis and a yield of 2.6%. The ex-dividend date of this dividend was Friday, October 17th. Colgate-Palmolive’s payout ratio is currently 58.26%.

Wall Street Analyst Weigh In

A number of analysts recently commented on CL shares. Wells Fargo & Company dropped their price target on shares of Colgate-Palmolive from $80.00 to $77.00 and set an “underweight” rating on the stock in a research note on Monday, November 3rd. Raymond James Financial dropped their target price on Colgate-Palmolive from $105.00 to $95.00 and set an “outperform” rating on the stock in a research report on Monday, October 20th. JPMorgan Chase & Co. reduced their price target on Colgate-Palmolive from $88.00 to $87.00 and set an “overweight” rating for the company in a research report on Monday, November 3rd. Citigroup decreased their price objective on Colgate-Palmolive from $105.00 to $95.00 and set a “buy” rating on the stock in a research note on Monday, November 3rd. Finally, Bank of America reduced their target price on Colgate-Palmolive from $98.00 to $88.00 and set a “buy” rating for the company in a report on Wednesday, October 8th. Nine analysts have rated the stock with a Buy rating, five have given a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat.com, the company presently has an average rating of “Moderate Buy” and an average price target of $89.87.

Colgate-Palmolive Company Profile

Colgate-Palmolive Company, together with its subsidiaries, manufactures and sells consumer products in the United States and internationally. It operates through two segments: Oral, Personal and Home Care; and Pet Nutrition. The Oral, Personal and Home Care segment offers toothpaste, toothbrushes, mouthwash, bar and liquid hand soaps, shower gels, shampoos, conditioners, deodorants and antiperspirants, skin health products, dishwashing detergents, fabric conditioners, household cleaners, and other related items.